The Department of Autism Research at ANTIBIOSTRESS CLINICS is committed to advancing autism research through scientific rigor, clinical responsibility, data protection, respect for persons, and ethical innovation.

As the FIAP® ecosystem develops toward construct validation, translational stratification, pilot studies, and future digital implementation, ethical responsibility must remain central.

This is particularly important in autism research, where biological data, developmental profiles, family context, digital health information, and AI-assisted interpretation may involve sensitive personal and clinical information.

The Department’s ethical commitment is based on a clear principle:

Precision autism research must support dignity, equity, transparency, and individualized understanding without reducing individuals to biological scores, algorithmic profiles, or rigid categories.

FIAP® constructs and FIAP®-Digital are being developed to support scientific interpretation and future clinician-guided care planning, not to label, stigmatize, replace professional judgment, or create deterministic predictions.

Every individual with autism must be understood as a whole person, not only through clinical symptoms, biological markers, behavioral measures, or digital profiles.

FIAP®-based research must protect:

• personal dignity; 
• developmental individuality; 
• neurodiversity; 
• family context; 
• lived experience; 
• cultural and social identity; 
• personal strengths and support needs. 

The goal is not to classify individuals narrowly, but to better understand what may support their development, engagement, adaptation, and well-being.

FIAP®-Digital is conceptualized as a clinician-guided, interpretable, AI-assisted framework.

It is not intended to function as an autonomous diagnostic system, an automated treatment prescriber, or a replacement for professional judgment.

Any future AI-assisted outputs must be interpreted by qualified professionals who can consider clinical history, developmental context, family priorities, environmental factors, and individual needs.

Precision care tools must be understandable to clinicians, researchers, families, and stakeholders.

The Department prioritizes interpretable constructs rather than opaque algorithmic outputs.

FIAP®-Digital should make clear:

• what data are being used; 
• what constructs are being estimated; 
• what the limits of interpretation are; 
• what uncertainty remains; 
• how outputs should and should not be used; 
• why clinician oversight is required. 

No FIAP® construct, translational profile, or FIAP®-Digital output should be used as a clinical decision tool before appropriate validation.

Responsible implementation requires:

• construct validation; 
• measurement reliability; 
• clinical interpretability; 
• longitudinal testing; 
• feasibility assessment; 
• bias evaluation; 
• ethical review; 
• professional oversight; 
• transparent communication of limitations. 

Until validated, FIAP® constructs should be presented as scientific frameworks under development, not as established diagnostic instruments or treatment algorithms.

Autism precision research may involve sensitive information, including biological, physiological, developmental, behavioral, therapeutic, family, and digital health data.

The Department is committed to responsible data practices, including:

• informed consent; 
• data minimization; 
• privacy protection; 
• secure storage; 
• restricted access; 
• confidentiality; 
• responsible data sharing; 
• clear communication about data use; 
• compliance with applicable privacy and research ethics standards. 

Data should be collected only when scientifically justified and ethically appropriate.

Precision autism research must avoid creating new forms of inequity.

AI-assisted tools and stratification models may produce biased or misleading outputs if they are developed using narrow, incomplete, or non-representative data.

The Department’s approach emphasizes:

• inclusive research design; 
• careful attention to bias; 
• culturally sensitive interpretation; 
• accessibility for diverse families; 
• avoidance of algorithmic discrimination; 
• equitable benefit from scientific innovation; 
• recognition of social and environmental determinants of care access. 

Precision care should expand access and fairness, not deepen disparities.

Biological burden, energetic capacity, therapeutic engagement, and neuroplastic capacity must not be interpreted as fixed labels or deterministic judgments.

A profile should never be used to define a person’s worth, potential, prognosis, or eligibility for support.

FIAP® profiles are intended to help identify support needs and intervention conditions, not to limit opportunity.

For example:

high biological burden should indicate a need for better biological and developmental support;

reduced energetic capacity should indicate the need for pacing, adaptation, and reserve support;

engagement vulnerability should indicate the need to improve therapeutic accessibility;

limited current accessibility should not be interpreted as lack of potential.

Ethical autism research must respect the perspectives of individuals with autism, families, caregivers, clinicians, educators, and community partners.

The Department values research and translation that are responsive to:

• family priorities; 
• caregiver experience; 
• developmental context; 
• clinical realities; 
• cultural values; 
• accessibility needs; 
• community concerns; 
• lived experience. 

Future pilot studies and implementation phases should include stakeholder engagement whenever appropriate.

Scientific innovation must be communicated carefully.

The Department avoids overstating the readiness of developing constructs or digital tools.

Communication should clearly distinguish between:

• conceptual frameworks; 
• manuscripts under review; 
• validated constructs; 
• pilot-study findings; 
• clinical tools; 
• digital prototypes; 
• implementation-ready systems. 

This distinction protects scientific credibility and prevents misunderstanding.

FIAP®-Digital is being developed around the principle that AI should assist—not replace—clinical reasoning.

Future AI-assisted functions may include:

• organizing multimodal data; 
• estimating validated constructs; 
• identifying possible translational profiles; 
• tracking longitudinal changes; 
• supporting clinician-guided interpretation; 
• assisting precision-care planning. 

However, final interpretation and care decisions must remain under qualified professional oversight.

FIAP®-Digital is intended to prioritize interpretability.

Instead of producing opaque predictions, the platform is envisioned to organize information around clinically meaningful constructs:

• Biological Burden Index — BBI; 
• Therapeutic Engagement Index — TEI; 
• energetic capacity; 
• adaptive neurodevelopmental window accessibility; 
• neuroplastic capacity; 
• translational profiles. 

This construct-based structure is intended to make AI-assisted outputs easier to review, challenge, contextualize, and refine.

Human oversight is essential at every stage of FIAP®-Digital development and use.

This includes:

• clinical review of outputs; 
• researcher review of model assumptions; 
• ethical review of study protocols; 
• transparent documentation of limitations; 
• accountability for interpretation; 
• mechanisms to correct errors; 
• ongoing monitoring for bias or misuse. 

The responsibility for interpretation must remain human, professional, and ethically governed.

Future FIAP® pilot studies should be designed with strong ethical safeguards.

These may include:

• research ethics board review where required; 
• clear informed consent procedures; 
• explanation of study purpose and limitations; 
• privacy and confidentiality protections; 
• appropriate handling of biological and digital data; 
• risk minimization; 
• attention to family burden; 
• feedback procedures that avoid overinterpretation; 
• communication of results in a cautious and supportive manner. 

Pilot studies should evaluate not only scientific feasibility, but also acceptability, fairness, usability, and potential unintended consequences.

A central ethical aim of the FIAP® ecosystem is therapeutic equity.

Therapeutic equity means that individuals should have access to interventions that are not only available, but also biologically, developmentally, contextually, and relationally accessible.

This perspective reframes precision care as an equity issue.

If a person does not respond to an intervention, the question should not only be whether the treatment “failed.” It should also be whether the intervention was accessible under the person’s biological, developmental, energetic, emotional, and contextual conditions.

This ethical orientation supports the broader FIAP® vision: moving from heterogeneity toward individualized accessibility and meaningful support.

The Department of Autism Research is committed to developing the FIAP® ecosystem through responsible, transparent, clinician-guided, and ethically grounded science. Our goal is to ensure that precision autism research supports dignity, equity, interpretability, validation, and individualized care without replacing professional judgment or reducing individuals to algorithmic profiles.